- Recruiting
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Sponsor:
Emory University
Collaborators:
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Location
United States, Georgia
ClinicalTrials.gov Identifier: NCT05204160
Official Title: Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy
First Posted: January 24, 2022
Click here for details on ClinicalTrials.gov
Biological: Pembrolizumab
Keytruda
Lambrolizumab
MK-3475
Pembrolizumab
PEMBROLIZUMAB
SCH 900475